Board of Directors
Board of Directors
Steven B. Gerber, M.D.
Chairman of the Board
HemaCare Corporation
Steven B. Gerber, M.D. was elected Chairman of the Board in May 2009, and has been a director of the Company since October 2003. A board-certified Internist and Cardiologist with subspecialty training in Nuclear Cardiology, Dr. Gerber earned his BA in Psychology at Brandeis University, his MD at Tufts University, and his MBA at UCLA.
Dr. Gerber is currently a board member and audit committee chair for privately-held iTherX Pharmaceuticals, a member of the Board of Overseers at Tufts University School of Medicine, and a Medical Expert for the U.S. Social Security Administration. From September 2003 through January 2007 Dr. Gerber served on the Board of Directors of Hypertension Diagnostics (HDII.OTCBB), and from January 2006 through February 2007 Dr. Gerber also served on the Board of Directors of Conor Medsystems (CONR.NASDAQ).
In October 2007, Dr. Gerber successfully completed the UCLA Directorship Training and Certification Program. Dr. Gerber is Chairman of the Audit Committee and the Corporate Governance and Nominating Committees.
Terry Van Der Tuuk
President
VanKan, Inc.
Terry Van Der Tuuk has been a director of the Company since May 2003.
Mr. Van Der Tuuk founded Graphic Technology, Inc. in 1978 and took it public in 1983 as Chairman and President. In 1989, Mr. Van Der Tuuk sold the Company to Nitto Denko of Osaka, Japan and continued as Vice Chairman until 2003, when he retired from GTI. Mr. Van Der Tuuk is President of VanKan, Inc, a Kansas based venture capital firm which invests in privately held companies in the Midwest area. Mr. Van Der Tuuk served on several educational boards, including The Wharton School, University of Pennsylvania, and currently serves on the boards of several privately held companies.
Mr. Van Der Tuuk received his Bachelor of Science degree from Michigan State University and his Masters of Business Administration degree from The Wharton School, University of Pennsylvania. Mr. Van Der Tuuk is a member of the Audit and Compensation Committees.
Julian Steffenhagen
Director
HemaCare Corporation
Julian Steffenhagen served as Chairman of the Board from September 2002 through May 2009 and as Interim Chief Executive Officer from June 2007 through September 2008. Mr. Steffenhagen joined the board of directors in 1997.
Over a period of 27 years, Mr. Steffenhagen held several management positions at Beckman Coulter, Inc., an international manufacturer of systems for biomedical testing in life sciences research and clinical diagnostics. At his retirement in January 2007, he held the position of Senior Vice President.
Mr. Steffenhagen earned his Bachelor of Science and Master of Science degrees in mechanical engineering, and his Master of Business Administration degree from the University of Michigan. Mr. Steffenhagen has served on the Audit and Compensation Committees.
Teresa S. Sligh, M.D.
President and Medical Director
Translational Research Group, Inc.
Teresa S. Sligh, M.D. has been a director of the Company since May 2006.
Since 2003, Dr. Sligh has been the President and Medical Director of Translational Research Group, Inc. and has served as the Chief Medical/Strategy Officer for Capital Technology Information Services, Inc.
Dr. Sligh completed two years of post graduate medical training in Internal Medical at Presbyterian Hospital of Dallas, Texas, and received her M.D. degree at Texas A&M College of Medicine. She received her Bachelor of Science degree in biochemistry from the University of New Mexico. Dr. Sligh is the Chairwoman of the Quality Assurance Committee and a member of the Compensation Committee.
Pete van der Wal
President and Chief Executive Officer
HemaCare Corporation
Peter van der Wal has been President and Chief Executive Officer and a director of the Company since February 2010. Mr. van der Wal also served as Chief Financial Officer of the company from February 2010 until August 2010. From November 2009 until February 2010, Mr. van der Wal was HemaCare's Vice President of Sales and Marketing. From May 2008 through November 2009, Mr. van der Wal was President and Chief Executive Officer of Comprehensive Imaging Solutions. Previously Mr. van der Wal was President and Chief Executive Officer of van der Wal Properties, Inc. from 2001 through 2007, Vice President of Business Development for Phormax Corporation from 2000 through 2001, and Senior Vice President, Marketing, Business Development for Comprehensive Medical Imaging, a division of Syncor International Corporation, from 1998 through 1999. From 1989 through 1998, Mr. van der Wal held a succession of positions at Syncor International Corporation with increasing sales and operations management responsibilities including Director of Sales and General Manager.
Mr. van der Wal received his Bachelor of Science degree in Biology and Marketing from the University of Maryland, and his Masters degree in Business Administration from George Mason University. In June 2010, Mr. van der Wal successfully completed the UCLA Directorship Training and Certification Program.
Mr. van der Wal brings strong leadership, entrepreneurial, marketing and business development skills to the Board from his experience starting and managing businesses as well as his executive positions with several health care services companies.
